Moreover, the 36-month beta value for FBIO is 1.78. Analysts have varying opinions on the stock, with 1 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for FBIO is 21.13M and currently, short sellers hold a 15.91% of that float. On June 13, 2025, FBIO’s average trading volume was 216.74K shares.
FBIO) stock’s latest price update
The stock price of Fortress Biotech Inc (NASDAQ: FBIO) has dropped by -6.67 compared to previous close of 2.10. Despite this, the company has seen a gain of 4.26% in its stock price over the last five trading days. globenewswire.com reported 2025-06-09 that National TV Segment Highlights FDA-Approved Treatment for Rosacea Segment premiered on Monday, June 9 and will be rebroadcast on Thursday, June 19, at 7:30 a.m. PT/ ET SCOTTSDALE, Ariz.
FBIO’s Market Performance
Fortress Biotech Inc (FBIO) has experienced a 4.26% rise in stock performance for the past week, with a 12.64% rise in the past month, and a 20.99% rise in the past quarter. The volatility ratio for the week is 5.56%, and the volatility levels for the past 30 days are at 3.60% for FBIO. The simple moving average for the past 20 days is 4.37% for FBIO’s stock, with a 10.80% simple moving average for the past 200 days.
Analysts’ Opinion of FBIO
Many brokerage firms have already submitted their reports for FBIO stocks, with ROTH MKM repeating the rating for FBIO by listing it as a “Buy.” The predicted price for FBIO in the upcoming period, according to ROTH MKM is $10 based on the research report published on March 15, 2024 of the previous year 2024.
Ladenburg Thalmann, on the other hand, stated in their research note that they expect to see FBIO reach a price target of $6. The rating they have provided for FBIO stocks is “Buy” according to the report published on August 04th, 2022.
The Benchmark Company gave a rating of “Buy” to FBIO, setting the target price at $9 in the report published on October 02nd of the previous year.
FBIO Trading at 14.07% from the 50-Day Moving Average
After a stumble in the market that brought FBIO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -32.18% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at FBIO starting from Fortress Biotech, Inc., who sale 100,000 shares at the price of $1.29 back on May 29 ’25. After this action, Fortress Biotech, Inc. now owns 6,122,249 shares of Fortress Biotech Inc, valued at $129,000 using the latest closing price.
ROSENWALD LINDSAY A MD, the PRESIDENT, CEO & CHAIRMAN of Fortress Biotech Inc, purchase 763,359 shares at $1.84 during a trade that took place back on Sep 23 ’24, which means that ROSENWALD LINDSAY A MD is holding 3,657,264 shares at $1,404,581 based on the most recent closing price.
Stock Fundamentals for FBIO
Current profitability levels for the company are sitting at:
- -1.66 for the present operating margin
- 0.67 for the gross margin
The net margin for Fortress Biotech Inc stands at -0.71. The total capital return value is set at -0.92. Equity return is now at value -181.84, with -24.02 for asset returns.
Based on Fortress Biotech Inc (FBIO), the company’s capital structure generated 0.77 points at debt to capital in total, while cash flow to debt ratio is standing at -0.74. The debt to equity ratio resting at 3.34. The interest coverage ratio of the stock is -7.93.
Currently, EBITDA for the company is -104.49 million with net debt to EBITDA at 0.19. When we switch over and look at the enterprise to sales, we see a ratio of 0.71. The receivables turnover for the company is 3.21for trailing twelve months and the total asset turnover is 0.32. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.72.
Conclusion
To wrap up, the performance of Fortress Biotech Inc (FBIO) has been better in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
